Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PT...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-oncology 2012-04, Vol.107 (2), p.225-232
Hauptverfasser:	Lieberman, Frank, Yazbeck, Victor, Raptis, Anastasios, Felgar, Raymond, Boyiadzis, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies B-Lymphocytes - metabolism B-Lymphocytes - pathology Brain - pathology Central nervous system Central Nervous System Diseases - complications Central Nervous System Diseases - diagnosis Central Nervous System Diseases - etiology Epstein-Barr virus Female Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunoproliferative diseases Immunosuppression Ki-67 Antigen - metabolism Lymphoproliferative Disorders - complications Lymphoproliferative Disorders - diagnosis Lymphoproliferative Disorders - etiology Magnetic Resonance Imaging Medicine Medicine & Public Health Monoclonal antibodies Neurology Oncology PAX5 Transcription Factor - metabolism posttransplant lymphoproliferative disorders Ribosomal Proteins - metabolism rituximab RNA-Binding Proteins - metabolism stem cell transplantation Topic Review Transplantation, Homologous - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PTLD there is no consensus on optimal treatment. We report a patient who developed Epstein-Barr virus related primary CNS-PTLD following allogeneic HSCT who was treated with the monoclonal anti-CD20 antibody rituximab and reduction of immunosuppression. In addition, we review the literature and discuss treatment options for patients with primary CNS-PTLD following allogeneic HSCT.
ISSN:	0167-594X 1573-7373
DOI:	10.1007/s11060-011-0739-6